Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial
Linda‐Gail Bekker, Surita Roux, Elaine Sebastien, et al.
The Lancet HIV (2017) Vol. 5, Iss. 2, pp. e68-e78
Open Access | Times Cited: 108

Showing 1-25 of 108 citing articles:

Preexposure Prophylaxis for the Prevention of HIV Infection
Roger Chou, Christopher Evans, Adam Hoverman, et al.
JAMA (2019) Vol. 321, Iss. 22, pp. 2214-2214
Open Access | Times Cited: 222
HIV pre‐exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery
Connie Celum, Sinéad Delany‐Moretlwe, Jared M. Baeten, et al.
Journal of the International AIDS Society (2019) Vol. 22, Iss. S4
Open Access | Times Cited: 203
The influence of HIV‐related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study
Jennifer Velloza, Nomhle Khoza, Fiona Scorgie, et al.
Journal of the International AIDS Society (2020) Vol. 23, Iss. 3
Open Access | Times Cited: 164
Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations
Éamon Ó Murchú, Liam E. Marshall, Conor Teljeur, et al.
BMJ Open (2022) Vol. 12, Iss. 5, pp. e048478-e048478
Open Access | Times Cited: 139
PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial
Connie Celum, Sybil Hosek, Mandisa Tsholwana, et al.
PLoS Medicine (2021) Vol. 18, Iss. 6, pp. e1003670-e1003670
Open Access | Times Cited: 131
A Gap Between Willingness and Uptake: Findings From Mixed Methods Research on HIV Prevention Among Black and Latina Transgender Women
Tonia Poteat, Andrea L. Wirtz, Mannat Malik, et al.
JAIDS Journal of Acquired Immune Deficiency Syndromes (2019) Vol. 82, Iss. 2, pp. 131-140
Open Access | Times Cited: 124
PrEP rollout in Africa: status and opportunity
Elizabeth Irungu, Jared M. Baeten
Nature Medicine (2020) Vol. 26, Iss. 5, pp. 655-664
Closed Access | Times Cited: 104
Daily and event‐driven pre‐exposure prophylaxis for men who have sex with men in Belgium: results of a prospective cohort measuring adherence, sexual behaviour and STI incidence
Béa Vuylsteke, Thijs Reyniers, Irith De Baetselier, et al.
Journal of the International AIDS Society (2019) Vol. 22, Iss. 10
Open Access | Times Cited: 99
Preexposure Prophylaxis for the Prevention of HIV
Roger Chou, Hunter Spencer, Christina Bougatsos, et al.
JAMA (2023) Vol. 330, Iss. 8, pp. 746-746
Open Access | Times Cited: 26
Event-driven PrEP beyond cisgender men who have sex with men
Whitney C. Irie, Melanie R. Nicol, Meredith E. Clement, et al.
The Lancet HIV (2025)
Closed Access | Times Cited: 1
Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial
Lynda Stranix‐Chibanda, E.L. Hamilton, Julie Ngo, et al.
The Lancet HIV (2025)
Open Access | Times Cited: 1
Choosing Between Daily and Event-Driven Pre-exposure Prophylaxis: Results of a Belgian PrEP Demonstration Project
Thijs Reyniers, Christiana Nöstlinger, Marie Laga, et al.
JAIDS Journal of Acquired Immune Deficiency Syndromes (2018) Vol. 79, Iss. 2, pp. 186-194
Open Access | Times Cited: 79
Provider perspectives on PrEP for adolescent girls and young women in Tanzania: The role of provider biases and quality of care
Nanlesta Pilgrim, Nrupa Jani, Sanyukta Mathur, et al.
PLoS ONE (2018) Vol. 13, Iss. 4, pp. e0196280-e0196280
Open Access | Times Cited: 76
Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions
Ioannis Hodges-Mameletzis, Virginia A. Fonner, Shona Dalal, et al.
Drugs (2019) Vol. 79, Iss. 12, pp. 1263-1276
Closed Access | Times Cited: 64
Global implementation of PrEP for HIV prevention: setting expectations for impact
Maria Pyra, Jessica E. Haberer, Nina Hasen, et al.
Journal of the International AIDS Society (2019) Vol. 22, Iss. 8
Open Access | Times Cited: 61
Current and Future PrEP Medications and Modalities: On-demand, Injectables, and Topicals
Matthew R. Beymer, Ian W. Holloway, Craig Pulsipher, et al.
Current HIV/AIDS Reports (2019) Vol. 16, Iss. 4, pp. 349-358
Open Access | Times Cited: 57
End‐user preference for and choice of four vaginally deliveredHIVprevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study
Elizabeth Montgomery, Mags Beksinska, Nyaradzo Mgodi, et al.
Journal of the International AIDS Society (2019) Vol. 22, Iss. 5
Open Access | Times Cited: 55
Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial
Katherine Gill, Leigh F. Johnson, Janan Dietrich, et al.
The Lancet Child & Adolescent Health (2020) Vol. 4, Iss. 12, pp. 875-883
Open Access | Times Cited: 53
Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies
Raphael J. Landovitz, Tao Li, Juan Yang, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 5, pp. 1197-1207
Open Access | Times Cited: 7
Contexts of vulnerability and the acceptability of new biomedical HIV prevention technologies among key populations in South Africa: A qualitative study
Millicent Atujuna, Peter A. Newman, Melissa Wallace, et al.
PLoS ONE (2018) Vol. 13, Iss. 2, pp. e0191251-e0191251
Open Access | Times Cited: 54
Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study
Robert M. Grant, Sharon Mannheimer, James P. Hughes, et al.
Clinical Infectious Diseases (2018) Vol. 66, Iss. 11, pp. 1712-1721
Open Access | Times Cited: 51
Acceptability of a long‐acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076)
Elizabeth E. Tolley, Sue Li, Sahar Z. Zangeneh, et al.
Journal of the International AIDS Society (2019) Vol. 22, Iss. 10
Open Access | Times Cited: 51
Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies
Sarah E. Rutstein, Dawn K. Smith, Shona Dalal, et al.
The Lancet HIV (2020) Vol. 7, Iss. 10, pp. e721-e730
Open Access | Times Cited: 50
Scaling up pre-exposure prophylaxis in sub-Saharan Africa
Nadia Ahmed, Carey Pike, Linda‐Gail Bekker
Current Opinion in Infectious Diseases (2018) Vol. 32, Iss. 1, pp. 24-30
Closed Access | Times Cited: 47
The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth
Elizabeth Montgomery, Millicent Atujuna, Emily Krogstad, et al.
JAIDS Journal of Acquired Immune Deficiency Syndromes (2019) Vol. 80, Iss. 5, pp. 542-550
Open Access | Times Cited: 46
Page 1 - Next Page

Scroll to top